Sentence examples for primary median from inspiring English sources

However, in the paired serum samples, HER2 levels increased significantly between the time of primary (median 12.2 ng/ml, range 5.7 to 85.0 ng/ml) and metastasis (median 17.7 ng/ml, range 6.3 to 3,337.4 ng/ml; P < 0.001).

The median time to relapse did not differ by the site of primary (median 5.9 years, IQR (4.3 8.7) for axial tumours, median 6.9 years, IQR (4.5 11.3) for tumours on the limbs, p = 0.2 Mann–Whitney U test), although patients with tumours on the limbs were more likely to relapse very late (33% after 10 years) than those with axial tumours (19%).

The best survival was for patients with three or more primaries (median 10.9 years) and was similar to the expected survival for the age-matched and sex-matched general population (P=0.06991).

In the paired serum samples, EGFR levels decreased significantly between the time of primary diagnosis (median 56.3 ng/ml, range 29.1 to 142.7 ng/ml) and metastatic diagnosis (median 30.9 ng/ml, range 10.9 to 106.4 ng/ml; P < 0.001).

Ages of the patients ranged from 48 to 76 among patients with primary GBMs (median age 55), from 41 to 69 among patients with recurrent GBMs (median age 52), and from 40 to 73 among patients with meningiomas (median age 62).

In patients who developed a tumor recurrence we detected a significantly higher PTTG expression in primary tumors (median expression: 2.63) when compared to patients who did not develop a tumor recurrence (median expression: 1.29; P = 0.009).

The scan after 2 cycles of chemotherapy was performed within 3 days after the second cycle of chemotherapy to study the influence of chemotherapy on the FAZA distribution in the primary tumor (median 1 day after 18F-FDG PET).

Secondary cases were younger than primary cases (median 13 years vs. 20 years; p<0.0005).

For the primary PEC, median staining values were shown due to patient variability.

After an average follow-up of 3.9 years (range 2 6.5), 319 (45.6%) reached the primary outcome; median time to treatment failure was 11.5 months.

The results showed that the vaccine arm significantly extended primary endpoint median overall survival compared with control group (p<0.00001) (HR 0.760; 95% CI 0.644 to 0.896; p=0.001).